Search results for "Platinum Compounds"

showing 10 items of 102 documents

Chemotherapy of metastatic colon cancer in France: A population-based study

2021

International audience; Aims: to describe, using data from a cancer registry in a well-defined French population, the therapeutic strategies and survival of patients with metastatic colon cancer (mCC).Methods: all patients with synchronous mCC diagnosed within the 2005-2014 period recorded in the digestive cancers registry of Burgundy were included.Results: 1286 mCC patients were included (57% male), of which 34.5% did not receive any antitumor treatment. Both, advanced age (≥75 years) and the Charlson comorbidity score ≥2 were significantly associated with the absence of antitumor treatment. Among the patients treated with chemotherapy, 59 and 33% received at least two and three lines, res…

Malemedicine.medical_specialtyOrganoplatinum Compounds[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinAdenocarcinomaPopulation-basedTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyIn patientRegistrieseducationAgedRetrospective StudiesMetastatic colon cancerChemotherapyeducation.field_of_studyHepatologyMetastatic colorectal cancerbusiness.industryPalliative CareComorbidity scoreAge FactorsGastroenterologyMiddle Aged3. Good healthCancer registry[SDV] Life Sciences [q-bio]Population based study030220 oncology & carcinogenesisColonic NeoplasmsCamptothecinFemale030211 gastroenterology & hepatologyFluorouracilFrancebusiness
researchProduct

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a m…

2006

ABSTRACT Background: Combinations of gemcitabine–oxaliplatin, gemcitabine–5-fluorouracil (5-FU) and 5-FU–oxaliplatin have synergistic activity and nonoverlapping adverse effect profiles. This trial assessed efficacy and safety of the triple combination gemcitabine–oxaliplatin and infusional 5-FU in patients with locally advanced (n = 11) or metastatic (n = 32) pancreatic adenocarcinoma. Patients and methods: A total of 43 eligible patients were treated with intravenous infusions of gemcitabine (900 mg/m2 over 30 min), followed by oxaliplatin (65 mg/m2 over 2 h) and 5-FU (1500 mg/m2 over 24 h) on days 1 and 8 of a 21-day cycle. Results: Among all 43 patients, the tumor response rate was 19% …

Malemedicine.medical_specialtyTime FactorsOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchAdenocarcinomaDeoxycytidineGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLost to follow-upInfusions IntravenousAgedChemotherapyCardiotoxicitybusiness.industryCombination chemotherapyHematologyMiddle AgedGemcitabineChemotherapy regimenGemcitabineSurgeryOxaliplatinOxaliplatinPancreatic NeoplasmsSurvival RateTreatment OutcomeOncologyDisease ProgressionQuality of LifeFemaleFluorouracilbusinessmedicine.drugAnnals of Oncology
researchProduct

Iris-Like Tunable Aperture Employing Liquid-Crystal Elastomers

2014

A liquid-crystal elastomer (LCE) iris inspired by the human eye is demonstrated. With integrated polyimide-based platinum heaters, the LCE material is thermally actuated. The radial contraction direction, similar to a mammalian iris, is imprinted to the LCE by a custom-designed magnetic field. Actuation of the device is reproducible over multiple cycles and controllable at intermediate contraction states.

Materials scienceAperturePlatinum CompoundsLiquid crystal elastomerEyeElastomerBenzoatesOpticsBiomimetic MaterialsmedicineHumansGeneral Materials Sciencebusiness.industryMechanical Engineeringfemale genital diseases and pregnancy complicationsLiquid CrystalsMagnetic fieldMagnetic Fieldsmedicine.anatomical_structureAcrylatesElastomersMechanics of MaterialsHuman eyeIRIS (biosensor)businessMagnetic orientationPolyimideAdvanced Materials
researchProduct

Amidrazone Complexes from a Cascade Platinum(II)-Mediated Reaction between Amidoximes and Dialkylcyanamides

2013

The aryl amidoximes R'C6H4C(NH2)═NOH (R' = Me, 2a; H, 2b; CN, 2c; NO2, 2d) react with the dialkylcyanamide platinum(II) complexes trans-[PtCl2(NCNAlk2)2] (Alk2 = Me2, 1a; C5H10, 1b) in a 1:1 molar ratio in CHCl3 to form chelated mono-addition products [3a-h]Cl, viz. [PtCl(NCNAlk2){NH═C(NR2)ON═C(C6H4R')NH2}]Cl (Alk2 = Me2; R' = Me, a; H, b; CN, c; NO2, d; Alk2 = C5H10; R' = Me, e; H, f; CN, g; NO2, h). In the solution, these species spontaneously transform to the amidrazone complexes [PtCl2{NH═C(NR2)NC(C6H4R')NNH2}] (7a-h; 36-47%); this conversion proceeds more selectively (49-60% after column chromatography) in the presence of the base (PhCH2)3N. The observed reactivity pattern is specific …

Models MolecularC5H10Molecular StructureOrganoplatinum CompoundsArylchemistry.chemical_elementCrystallography X-RayAmidesMedicinal chemistryInorganic Chemistrychemistry.chemical_compoundchemistryCascadeOximesOrganic chemistryPhysical and Theoretical ChemistryPlatinumta116Inorganic Chemistry
researchProduct

Synthesis and NMR characterization of the cis and trans isomers of [Pt(II)(N9-adeH)2(pz)2] and X-ray crystallography of the trans isomer.

2007

The reaction of tetrapyrazine Pt(II) with adenine under basic conditions yielded two products both disubstituted by adenine and bound in all cases to the N-9 nitrogen of adenine. Crystals amenable to X-crystallographic analysis were obtained for one product which was consequently identified as trans-[Pt(II)(N9-adeH)2(pz)2](NO3)(4).H2O. The other product, though, was identified as the cis isomer based on extensive and comparative NMR structural studies whereby the two compounds were examined as both neutral and tetraprotonated species in solution. The major product of the reaction was unexpectedly the cis isomer, thus obtained in contrast to the trans effect, and the reason for this result i…

Models MolecularMagnetic Resonance SpectroscopyOrganoplatinum CompoundsStereochemistryTrans effectChemistryAdenineMolecular ConformationStereoisomerismCrystallography X-RayInorganic ChemistryPyrazinesX-ray crystallographyConformational isomerismCis–trans isomerismPlatinumDalton transactions (Cambridge, England : 2003)
researchProduct

Organometallic Oligomers Based on Bis(arylacetylide)bis(P-chirogenic phosphine)platinum(II) Complexes: Synthesis and Photonic Properties

2013

A series of P-chirogenic oligomers of the type (-C≡C-aryl-C≡C-PtL2-)n [L = (R)- and (S)-P(Ph)(iPr)(C17H35); aryl = 1,4-benzene, 2,1,3-benzothiadiazole] along the corresponding achiral analogues (L = PBu3) and model complexes PhC≡CPtL2C≡CPh were prepared from the ephedrine strategy and were fully characterized [(1)H, (31)P NMR; IR; small-angle X-ray scattering (SAXS); gel permeation chromatography (GPC); thermal gravimetric analysis (TGA); circular dichroism, UV-vis, and luminescence spectroscopy; photophysics, and degree of anisotropy measurements]. From the CD measurements, the chiral environment of the phosphine ligands is modestly felt by the aryl moieties. Concurrently, the TGA shows th…

Models MolecularPhotonsCircular dichroismThermogravimetric analysisMolecular StructureOrganoplatinum CompoundsAcetylenePhosphinesSmall-angle X-ray scatteringChemistryLigandArylMolecular Dynamics SimulationPhotochemistryInorganic ChemistryGel permeation chromatographychemistry.chemical_compoundPolymer chemistryPhysical and Theoretical ChemistryLuminescencePhosphineInorganic Chemistry
researchProduct

Triphenylphosphane Pt(II) complexes containing biologically active natural polyphenols: Synthesis, crystal structure, molecular modeling and cytotoxi…

2016

Platinum complexes bearing phosphane ligands in cis configuration with deprotonated flavonoids (3-hydroxyflavone, quercetin) and deprotonated ethyl gallate were synthesized starting from cis-[PtCl2(PPh3)(2)]. In all cases, O,O' chelate structures were obtained. While quercetin and ethyl gallate complexes are quite stable in solution, the 3-hydroxyflavonate complex undergoes a slow aerobic photodegradation in solution with formation of salicylic and benzoic acids. The X-ray diffraction structures of quercetin and ethyl gallate complexes are reported. Cell cycle studies (in the dark) of the complexes in two human cell lines revealed that the cytotoxic activity of the complex bearing 3-hydroxy…

Models MolecularPlatinum(II) complexesOrganoplatinum CompoundsMolecular modelStereochemistryPlatinum(II) complexes; Cytotoxic activity; Natural polyphenols; Flavonoids; DFTEthyl gallateCrystal structureCytotoxic activity; DFT; Flavonoids; Natural polyphenols; Platinum(II) complexesCrystallography X-Ray010402 general chemistry01 natural sciencesBiochemistryMedicinal chemistryDFTInorganic ChemistryHydrolysischemistry.chemical_compoundDeprotonationHumansChelationPhotodegradationCytotoxic activity DFT Flavonoids Natural polyphenols Platinum(II) complexesFlavonoidsCytotoxic activityCytotoxins010405 organic chemistryChemistryPolyphenols0104 chemical sciencesMCF-7 CellsNatural polyphenolsCis–trans isomerism
researchProduct

Energy transfers in monomers, dimers, and trimers of zinc(II) and palladium(II) porphyrins bridged by rigid Pt-containing conjugated organometallic s…

2009

A series of linear monomers (spacer-M(P)), dimers (M(P)-spacer-M'(P)), and trimers (M(P)-spacer-M'(P)-spacer-M(P)) of spacer/metalloporphyrin systems (M' = Zn, M = Zn, Pd, P = porphyrin, and spacer = trans-C(6)H(4)C[triple bond]CPtL(2)C[triple bond]CC(6)H(4)- (L = PEt(3))) including mixed metalloporphyrin compounds, were synthesized and characterized. The S(1) and T(1) energy transfers Pd(P)*--Zn(P) occur with rates of approximately 2 x 10(9) s(-1), S(1), and 0.15 x 10(3) (slow component) and 4.3 x 10(3) s(-1) (fast component), T(1). On the basis of a literature comparison with a related dyad, the Pt atom in the conjugated chain slows down the transfers. The excitation in the absorption ban…

Models MolecularTime FactorsOrganoplatinum CompoundsStereochemistryMetalloporphyrinsMolecular Conformationchemistry.chemical_elementZincConjugated system010402 general chemistryLigands01 natural sciences7. Clean energyAbsorptionInorganic Chemistrychemistry.chemical_compoundAtomtrimerPhysical and Theoretical ChemistryComputingMilieux_MISCELLANEOUSmetalloporphyrinenergy transfer010405 organic chemistrySpectrum AnalysiszincmonomerdimerpalladiumPorphyrin0104 chemical sciences3. Good health[CHIM.THEO]Chemical Sciences/Theoretical and/or physical chemistryCrystallographyMonomerchemistryAbsorption bandLuminescent Measurements[ CHIM.THEO ] Chemical Sciences/Theoretical and/or physical chemistryconjugated organometallic spacerDimerizationExcitationPalladium
researchProduct

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by int…

2020

International audience; Introduction The aim of this study was to identify prognostic factors of overall survival in patients with FIGO stage IIIc or IVa ovarian cancer (OC) treated by neo-adjuvant chemotherapy (NAC) followed by interval debulking surgery.Materials and methods Data from 483 patients with ovarian cancer were retrospectively collected, from January 1, 2000 to December 31, 2016, from the FRANCOGYN database, regrouping data from 11 centers specialized in ovarian cancer treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analysis were performed to define prognostic factors of overall survival.Results The median overall sur…

Neoplasm Residualmedicine.medical_treatmentGenes BRCA2FIGO Stage IIICGenes BRCA1Platinum CompoundsCarcinoma Ovarian EpithelialCohort Studies0302 clinical medicineAscitic FluidOverall survivalPeritoneal Lavage030212 general & internal medicineOvarian NeoplasmsUnivariate analysisCytoreduction Surgical ProceduresGeneral MedicineMiddle AgedPrognosisDebulkingNeoadjuvant Therapy3. Good healthSurvival RateOncology030220 oncology & carcinogenesisFemaleTaxoidsFranceOmentumCohort studymedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAntineoplastic Agents[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsInterval debulking surgeryNeoadjuvant chemotherapyPelvis03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerOvarian cancerMedian follow-upmedicineHumansNeoplasm InvasivenessAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryRetrospective cohort studymedicine.diseaseSurgery[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMultivariate AnalysisLymph Node Excision[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieSurgeryLymphadenectomyLymph NodesOvarian cancerbusinessEuropean Journal of Surgical Oncology
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct